These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1398471)

  • 1. Evaluation of GH paradoxical responses to TRH and LHRH in acromegalic patients during long-term treatment with octreotide.
    Merola B; Colao A; Cataldi M; Rossi E; Selleri A; Briganti F; Schettini G; Bellastella A; Lombardi G
    Horm Res; 1992; 37(1-2):18-22. PubMed ID: 1398471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ; Harris AG; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
    Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
    Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly.
    Pieters GF; Smals AE; Smals AG; von Gennep JA; Kloppenborg PW
    Acta Endocrinol (Copenh); 1987 Apr; 114(4):537-42. PubMed ID: 2883797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies.
    Colao A; Merola B; Ferone D; Calabrese MR; Longobardi S; Spaziante R; Di Renzo G; Annunziato L; Lombardi G
    Eur J Endocrinol; 1994 Jul; 131(1):14-9. PubMed ID: 8038903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal growth hormone responses to L-dopa and thyrotropin-releasing hormone in patients with acromegaly.
    Hanew K; Aida M; Tano T; Yoshinaga K
    Tohoku J Exp Med; 1977 Mar; 121(3):197-206. PubMed ID: 404727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly--the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone.
    Utsumi A; Hanew K; Sugawara A; Shimizu Y; Murakami O; Ikeda H; Yoshinaga K
    J Endocrinol Invest; 1992 Mar; 15(3):167-71. PubMed ID: 1624675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
    Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous responses to the long-term treatment of active acromegaly with octreotide.
    Chang CL; Kuo HF; Fang VS; Hwu CM; Lai TY; Yang HJ; Kwok CF; Ho LT
    Endocr J; 1996 Aug; 43(4):447-56. PubMed ID: 8930535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.